Latest News

The FDA has approved rebisufligene etisparvovec-hopf (Fayuvi), the first treatment designed to alter the course of mucopolysaccharidosis type IIIA.

This update came with no changes to the safety sections of labeling, with no new signals identified with longer follow-up.

Professional membership and experienced mentor leadership offer new pharmacy technicians a dual advantage, serving as a comprehensive training accelerator.

A biologic stewardship framework can enhance consistency, safety, and sustainability of biologic use in health systems.

The update shortens required observation to 6 to 8 hours from 22 to 24, easing tarlatamab administration in community settings for ES-SCLC.

Thomas Hope, MD, explains why radioligand therapies should be evaluated according to whether their clinical benefits outweigh their risks within the context of patients’ available cancer treatment options.

The approval is supported by data from the phase 3 FINE-ONE clinical trial.

The randomized ALLIANCE A051701 trial closed early when treatment-related toxicity and mortality were increased without improving PFS in patients with newly diagnosed double-hit lymphoma.

Artificial intelligence (AI) transforms a chaotic, reactive process into an adaptive, proactive system that improves workflow and patient safety.

Robin Tumlinson, PharmD, BCOP, discusses how rapidly expanding bladder cancer options are creating new questions around treatment sequencing, toxicity management, biomarker testing, and multidisciplinary care.

With changes in Medicaid eligibility looming, hospitals must plan now to keep patient care gaps at bay.

Pharmacists are well equipped to manage DOAC therapy by providing initial education, adherence support, and safety monitoring.

A prospective observational study found microplastics more frequently and at higher levels in lung samples from patients with lung malignancies, although the findings do not establish that the particles cause cancer.

Helicobacter pylori exposure could be associated with approximately 22% of colorectal cancer cases worldwide.

Eight-year phase 3 ADAURA trial data show adjuvant osimertinib boosts survival in patients with resected EGFR-mutant NSCLC.

Pharmacists play a key role in guiding age- and risk-based vaccination decisions to protect against invasive and noninvasive disease.

As pharmaceutical markets become increasingly dynamic, health systems may benefit from shifting toward unit-level economic frameworks that evaluate cost and margin performance.

September highlights Blood Cancer Awareness Month, focusing on education, early diagnosis, and support for multiple myeloma, lymphoma, and leukemia patients.

Machine-learning and multiple-imputation models could help researchers estimate missing baseline Eastern Cooperative Oncology Group performance status in advanced prostate cancer.

Gepotidacin and zoliflodacin show comparable efficacy to standard care for urogenital gonorrhea, offering promising alternatives given the recent rise in antimicrobial resistance.

At the 2026 New England Institute of Ambulatory Care Pharmacists (NEIAP) Annual Forum, Jennifer Goldman detailed how monitoring data drive engagement—and how a new dual sensor readies pharmacists for ketone alerts.